Methods have been developed for the detection of exposure to carcinogens and other DNA-damaging agents in experimental animals and humans, through the detection of carcinogens or metabolic derivatives of them in body fluids or adducts bound covalently to DNA or hemoglobin. These methods are being applied in studies of exposure to environmental carcinogens, the results of which demonstrate their adequacy for detecting ambient exposures. The successful use of urinary markers of genotoxic exposures has been reported with respect to nitrosoproline as an indicator of exposure to N-nitroso compounds. The same approach has been used to detect aflatoxin B, (AFB,) metabolites and AFB,-N7-Gua as markers of exposure to aflatoxin B,. Detection of adducts formed between genotoxic agents and hemoglobin has been reported in studies of populations occupationally exposed to ethylene oxide, in which 3-hydroxyhistidine and 3-hydroxyvaline have been measured, and in smokers, whose hemoglobin has been found to contain levels of 4-aminobiphenyl and 3-hydroxyvaline that were correlated with the frequency of cigarette smoking. Albumin adducts of AFB, have been identified in exposed people and their levels correlated with ingested amounts of the carcinogen.
INTRODUCTION
URRENT RESEARCH IN THE FIELD of markers of carcinogen exposure is based on knowledge C about mechanisms of carcinogenesis and mutagenesis together with highly sophisticated analytical methods, with the objective of detecting molecular and cellular events that may be predictive of health risks. This is a timely and important area of research endeavor, since the process of risk assessment is finding increasing application by regulatory decision making bodies in the formulation of policies intended to minimize health risks resulting from exposure to hazardous substances. By current definition, the process of risk assessment includes three elements: hazard identification, dose-response assessment, and risk characterization. Exposure assessment and epidemiology data are key components of the dose-response assessment, the objective of which is to define dose-incidence relationships for adverse health effects (such as cancer) in human populations. These components, together with animal bioassay data, appropriate extrapolation of information concerning dose-effects in animals, and interspecies differences in response, effectively determine the quantitative features of the risk estimation and are therefore of critical importance.
The sensitivity of epidemiologic studies of potential health significance of environmental chemicals, including carcinogens, is seriously compromised by the lack of quantitative exposure data for individuals in exposed populations. Monitoring data on levels of compounds in environmental media often represent the only information available, and average population exposure is therefore the only quantitative parameter that can be calculated. Biological monitoring (i.e., measurements that can be made on cells, tissues, or body fluids of exposed people) has the objective of defining "dose" (internal or biologically effective) on an individual basis. They therefore provide an indication not only of exposure but also of the amount absorbed and metabolically transformed to activated derivatives (viz., the fraction bound to functionally important cellular sites). Biological monitoring data thus provide information that complement environmental monitoring data, and because they can be interpreted in the context of known mechanisms of action, they are more directly relevant to assessment of health risks. Exposure assessment strategies based on biological monitoring can therefore be designed to take into account exposures through multiple routes, integrate the consequences of intermittent as well as continuous exposures, and also provide evidence of total risk from multiple sources and to multiple agents.
The subjects of biological monitoring and its applications in the field that has come to be known as molecular epidemiology have been the subjects of several recent reviews. This discussion will emphasize detection methodology, and will summarize currently available information on carcinogen exposure. Broader perspective on the field can be found in several more comprehensive reviews.(l-81
INDICATORS OF GENOTOXIC EXPOSURES
Methods for detecting exposures to DNA-damaging agents are classifiable into two categorical types: measurements of levels of genotoxic chemicals, their metabolites and/or derivatives in cells, tissues, body fluids, or excreta; and measurements of biological responses such as cytogenetic changes in exposed individuals. This discussion will emphasize recent developments in the former category, although important advances are also being made in the development and application of biological indicators of genotoxic exposures. These include mutation markers based on altered phenotype (e.g., HPRT deficiency in peripheral leukocytes); altered gene product (e.g., mutant glycophorin in erythrocyte membranes); gene inactivation (loss of specific mRNA); or altered DNA sequences (RFLP, or translocations involving oncogene sequences). Chromosomal markers that have been useful in detecting damage from genotoxic agents include structural aberrations, sister chromatid exchanges, and aneuploidy. The presence of micronuclei in circulating erythroid cells provides an additional index of genotoxicity.
Chemical dosimeters for several types of genotoxic exposures are also available for the detection of carcinogen exposures. Major approaches depend on chemical or immunologic analytical methods for the detection of carcinogens or their metabolic derivatives in blood or urine. Mutation assays in bacteria have also been used to detect the presence of mutagens in urine in relation to environmental exposures. A third avenue of investigation has been the detection of covalent adducts formed between carcinogens/mutagens and cellular macromolecules such as proteins (e.g., hemoglobin) or cellular DNA, or excreted in urine.
DETECTION OF CARCINOGEN EXPOSURE IN HUMANS
Development of these detection methodologies has permitted studies designed to evaluate their adequacy for detecting exposure to carcinogens in humans. Results of several such studies have been published, and Tables 1-3 summarize representative data from reports dealing with biomonitoring of exposure of humans to genotoxic agents of a variety of types and sources. Table 1 summarizes findings from studies in which excretion of urinary markers of interaction products of carcinogens with proteins or nucleic acids was measured. The daily excretion of nitrosamino acids was measured in Chinese population groups residing in areas of high or low risk for cancer of the esophagus.(9' This study was designed to gain evidence on a possible causative role for N-nitroso compounds, some of which are effective esophageal carcinogens in animals, as risk factors for humans. The substantially higher values observed in persons in the high-risk area indicate a higher level of exposure to these carcinogens during the study period. A similar approach was used(l01 to define the potential of inhaled cigarette smoke for endogenous N-nitrosation of amines. The data revealed not only the existence of a substantial background of endogenous nitrosation in nonsmoking controls but also a significant increase in smokers. An extensive investigation of variability in the excretion of nitrosoproline was conducted in healthy volunteer subjects, all but two of whom were nonsmokers.cI1) The average value for these subjects was very close to that for the nonsmoking controls and residents of the low-risk areas in the earlier studies. In each of these studies, ingestion of ascorbic acid was shown to lower the excretion rates, as expected. The general pattern of reported values indicates the usefulness of this measurement in detecting exposure to environmental nitrosating agents.
Urinary excretion of markers
Assessment of human exposure to aflatoxins by measurement of urinary excretion of the major DNA adduct has been reported in two studies. The technique of immunoaffinity purification coupled with high-performance liquid chromatography (HPLC) detection was used(!*) to identify the guanine adduct of aflatoxin BI in the urine of persons residing in a commune in Guangxi Province of the People's Republic of China (PRC), where direct analysis showed high dietary content of the carcinogen. The analytical method was adequate to detect the adduct in the urine of persons exposed at high levels, and also to quantify the excretion of aflatoxin MI, a metabolite, as well as unmetabolized carcinogen. Aflatoxin exposure was also measured by urinary excretion of the guanine adduct in populations living in areas with different liver cancer incidences in Kenya.cl3) The adduct was detected by HPLC used in combination with synchronous scanning fluorescence spectrophotometry, and it was present in 12% of a large series (983) of samples collected over a period of years in different areas of the country.
Two additional approaches based on analysis of urinary components have been suggested as potential monitors of genotoxic exposures. Measurement of 3-methyl adenine in urine has been suggested as an indicator of exposure to methylating agents. (14) A GC-MS method using singleion monitoring has been developed that is capable of detecting the methylated base in nominally unexposed individuals. Further validation of the method will be required to determine its usefulness as an exposure monitor. An HPLC assay for determining levels of free thymine glycol and thymidine glycol in urine is being developed(l5) as a noninvasive assay for oxidative DNA damage, since these compounds are products of DNA damage caused by ionizing radiation and other oxidative mutagens. The method was capable of measuring excretion rates of both compounds in healthy individuals, but has found only limited application in its present form.
Hemoglobin adducts
A summary of representative data on measurements of hemoglobin adducts derived from exposure to carcinogens is presented in Table 2 . Most of the work done to date has concerned the measurement of N-3-(2-hydroxyethyl)histidine (HEH) or hydroxyethylvaline (HV) as monitors of exposure to ethylene oxide. This methodology, in which the alkylated derivative was measured by GC-MS, was developed by Ehrenberg and his colleagues, and was used in the study of occupationally exposed workers.cI6) Average data shown in Table 2 for exposed subjects and unexposed controls indicate the sensitivity of the method. Additional findings of these studies indicated the general agreement of the data obtained in humans with those predicted from earlit.. studies in the mouse, and also demonstrated the superiority of the method for providing a cumulative measure of exposure compared to point monitoring of air levels. The same methodology was subsequently used(J7) in a study of workers in an ethylene oxide manufacturing plant, in which cytogenetic and immunologic endpoints were made simultaneously in the same individuals. These studies demonstrated a substantially higher background of HEH in their control subjects, and reported no significant difference between exposed and unexposed persons. Levels of HEH, as determined by GC-MS on protein hydrolysates in which the adduct was concentrated by ion exchange chromatography, were compared(l8) with levels of HV determined by GC-MS analysis of hemoglobin subjected to Edman degradation before analysis. The two methods of analysis gave consistent results, especially at high levels, and also higher levels of background alkylation (of unknown origin) were obtained in measurements of HEH than with HV. This suggested that the latter assay would show greater sensitivity in monitoring exposure to ethylene oxide. This method was subsequently applied in a study of cigarette smokers and nonsmokers(l9) in which an elevation of HV levels was observed in smokers that was quantitatively compatible with measured levels of ethylene in the smoke to which they were exposed.
A method has been developed (20) for the analysis of 4-aminobiphenyl covalently bound as the sulfinic acid amide to the 93-beta cysteine of human hemoglobin. The method involves hydrolysis of the hemoglobin followed by GC-MS determination of the parent amine after derivatization. Application of the method to smokers and nonsmokers revealed consistently elevated levels in smokers, but also detectable adducts of unknown origin in nonsmokers. When taken together, these results indicate the applicability of analysis of hemoglobin adducts as monitors of exposure to carcinogens of different structural types and mode of action.
Detection of BPDE adducts in DNA by immunoassay or chemical analysis
Results of several studies designed to determine exposure to the ubiquitous polycyclic aromatic hydrocarbon benzo(a)pyrene (BP), through the detection of derivatives covalently bound to DNA are summarized in Table 3 . Immunoassays and physicochemical methods were used to detect adducts formed through the major intermediate in the activation pathway, the benzo(a)pyrene-7,8-diol-9,lO-epoxide (BPDE). Immunoassays were applied in two modes, ELISA and USERIA, using both monoclonal antibodies and polyclonal antisera that recognize BPDE-DNA adducts, with various levels of cross-reactivity with structurally related congeners. In an early pilot study in humans, (2') it was demonstrated that the ELISA assay was capable of detecting adducts in DNA extracted from lung tumors as well as from nontumor tissue in lung cancer patients, but the small number of subjects studied precluded conclusions concerning exposure history. ELISA and USERIA assays have been used (22) to investigate the levels of BPDE-DNA adducts in the white blood cells of roofers and foundry workers exposed to high levels of BP. Adducts were detected in a significant proportion of exposed individuals and also in two of nine control subjects, both of whom were cigarette smokers. The technique of synchronous scanning fluorimetric spectrophotometry (SSFS) was applied in the analysis of DNA of white blood cells (WBC) collected from workers in an aluminum plant for the presence of BPDE-DNA adducts.(23)The limit of detection of this method as applied was about 1 adduct in 10' nucleotides. One sample of WBC DNA from the series of 30 exposed subjects showed the presence of a detectable level of BPDE. DNA from WBC of coke oven workers was analyzed by USERIA and by SSFS(24) to determine the frequency and levels of BPDE adducts as markers of exposure, since these workers are known to be exposed to high levels of BP and are also at an elevated risk of lung cancer. Approximately two-thirds of the workers had detectable levels of BPDE-DNA adducts as determined by immunoassay, and an even larger proportion showed spectral evidence of the presence of BPDE by the SSFS assay. Antibodies to the DNA adducts were also detected in the serum of 27% of the workers. Coke oven workers were also the subjects of a study (25) to evaluate the genotoxic effects of their occupational exposures through analysis of BPDE-DNA adducts, with simultaneous measurements of urinary excretion of PAH metabolites and air monitoring. As in the earlier study, DNA adducts were measured by USERIA and syndronous scanning fluorescence spectrophotometry (SSFS), and the sera were examined for the presence of anti-DNA adduct antibodies. The results agreed with those obtained earlier(24) in all respects. ELISA assays have been used (26) in the study of PAH adducts in the DNA of WBC collected from Finnish foundry workers classified as experiencing high, medium, or low levels of exposure, as well as unexposed control subjects. Mean levels of DNA adducts increased with exposure, and there was a highly significant difference between the control and pooled exposure group means. Immunoassay techniques have also been used to detect adducts of DNA-damaging agents other than BPDE. Radioimmunoassay of 06-methyldeoxyguanine was performed(27) on human esophageal and cardiac stomach mucosal DNA from tissue samples obtained during surgery in Linxian County, PRC, an area of high risk for both esophageal and stomach cancer. Similar analyses were conducted on samples collected from hospitals in Europe. Using this methodology, 06-meG was detected in about two-thirds of samples from the high risk area, as compared to 5 of 12 from the control area. Adduct levels were also higher in samples from people living in the high-risk areas. DNA adducts induced by the anticancer drug cis-diaminedichloroplatinum (11) were detected through application of ELISA methodology (28) in the WBC of cancer patients treated with the drug. Results indicated that the susceptibility of WBC to adduct formation is highly variable. ELISA methodology has also been used '29) to study adducts derived from cis-platinum in WBC of ovarian cancer patients being treated with the drug. The data showed that higher level of adduct formation correlated well with clinical responsiveness to the drug.
Detection of aromatic DNA adducts by 32P postlabeling
The postlabeling procedure developed by Randerath and his collaborators has been extensively applied to studies of DNA adduct formation in a variety of experimental systems, and the ability of the methodology to detect adducts of a large number of carcinogens (about 50) has been reported. The procedure has recently been extended to studies in humans, with results that can be summarized as follows. The presence of DNA adducts in human term placentas have been investigated(30) by both ELISA and by the 32P postlabeling assay. The immunoassay revealed a small but insignificant increase in BPDE adduct levels in placentas from smokers compared to nonsmokers. However, the postlabeling assay detected a number of adduct types, the major one being strongly related to maternal smoking during pregnancy. Subsequently, adduct levels in human bronchus and larynx from smokers were compared with those produced in mouse skin treated with cigarette tar.(") The human tissues were found to contain detectable levels of adducts, one of which (designated adduct 1) was identical to a major and persistent adduct formed in mouse skin. The postlabeling assay was also used(32' to investigate DNA adducts in exfoliated mucosal cells collected from the oral cavity of three groups at high risk for oral cancer. Five chromatographically distinct adducts were found in both the high-risk groups and nonsmoking controls. Individual adducts were detected in 30-90% of samples, and no adducts were found in high-risk groups that did not also appear in control groups. Thus, although the method was successful in detecting adducts derived from unknown sources, it did not differentiate between exposed and nonexposed populations. The same approach was used (33) to analyze the DNA from oral mucosal cells of cigarette smokers and nonsmokers to determine whether smoking-related adducts could be identified. Two chromatographically distinct adducts of unknown identity were found in smokers but not in nonsmokers. In addition, the levels of these major and several minor adducts were substantially higher in smokers. DNA from normal human bone marrow mononuclear and nonmononuclear cells was analyzed (34) for the presence of aromatic adducts. Ten of 10 individuals showed the presence of adducts, which were not present in fetal bone marrow but were present at lower levels in the DNA of peripheral WBC. The data suggested that the adducts resulted from environmental exposure to unidentified genotoxic agents. The postlabeling assay was also used (35) to analyze WBC DNA from foundry workers for the presence of adducts that might reflect differing levels of exposure to BP. Adducts were found in 10 of 10 workers at levels detectable by the analytical method, but none of these had the chromatographic properties characteristic of adducts derived from BP. Adducts were also identified in nonexposed control subjects. These results indicated significant interindividual differences in DNA binding among people receiving similar levels of exposure. WBC and placental DNA were investigated(36' for the possible presence of adducts derived from exposure of pregnant women to residential wood combustion smoke. Detectable levels of unidentified adducts were found in all placentas of exposed and nonexposed women; none of the nine adducts found was present in WBC DNA of any of the subjects. The results suggest that residential wood combustion smoke did not elicit aromatic DNA adducts at detectable levels, but that placental DNA contained detectable levels of adducts of unknown identity or origin.
WOGAN
These results demonstrate the ability of the postlabeling method to detect DNA damage arising from a variety of environmental exposures.
Available information thus indicates that adducts formed in people exposed to DNA-damaging agents of a variety of types can be detected and, in many instances, quantified by current immunologic and/or chemical methods. Application of these methodologies in well-designed longitudinal studies in humans will permit further evaluations of their validity and limitations in actual use.
DNA adducts and hemoglobin adducts as measures of exposure and susceptibility
Although additional technological refinement and validation will be required before many of the current methods will be routinely applicable in large-scale epidemiologic studies, it seems likely that some of them will come into broad application. In interpreting data generated by their application, careful attention must be paid to factors such as technological validity and limitations imposed by current knowledge about the biological significance of the endpoints they measure.
Concerning the use of DNA adduct levels as measures of exposure and cancer risk, virtually all of the available evidence comes from experimental systems, especially experiments in which adduct formation in carcinogen-treated animals was studied in relation to tumor formation in response to treatment. Most carcinogens have been shown to form complex spectra of DNA adducts, and qualitatively similar adduct profiles can be formed in sensitive and resistant species, strains, and/or tissues. Adduct persistence may or may not be related to susceptibility and/or target tissue specificity. In target tissues, maximum total adduct levels usually reflect carcinogen potency and dose, and maximum total adduct levels are linearly related to dose over a wide range. Many factors have been identified that can affect the levels of DNA adducts observed in cells of treated animals at any given time. The exposure-sampling interval can markedly affect observed levels, as determined by the pharmacokinetic properties of carcinogens of specific chemical types. An important component of this process is the propensity for metabolic activation, which can be affected by a variety of genetic as well as environmental factors (e.g., inducers or inhibitors). Exposure to protective agents such as antioxidants or other dietary ingredients can also exert marked effects. DNA repair capacity, as determined by genetic factors as well as kinetics (e.g., saturability) or modulating factors, is also an important determinant of adduct stability. These factors indicate the complexity of the problem of meaningful interpretation of DNA adduct levels as quantitative measures of exposure.
In relation to the use of DNA adduct levels as indicators of long-term risk, the situation is further complicated by additional factors. The target tissue at risk to a given genotoxic exposure is usually unknown, and reliance must be placed on measurements of adduct levels in surrogate cells such as peripheral WBC. The validity of the DNA analyzed for target cell DNA is difficult to assess. Extrapolation of DNA adduct levels as indicators of cancer risk necessarily entails simplifying assumptions about the multistage nature of the cancer process, which cannot be evaluated with current information. In addition, point measurements of DNA adduct levels may or may not provide evidence of multiple and variable exposures.
Protein adducts have no putative mechanistic role in carcinogenesis, and are primarily regarded only as measures of exposure. Evidence from experimental animals and from human studies supporting the interpretation of protein adduct levels as exposure monitors can be summarized as follows. Measurement of hemoglobin adducts has certain obvious technical advantages, since the protein can readily be obtained in abundant quantities. Sensitive and specific methods have been developed for two classes of carcinogens, and more are in the process of development. Carcinogens of diverse chemical structures have been shown to bind to hemoglobin in vivo. Adducts are stable over the erythrocyte's lifespan, thereby giving an integrated measure of multiple exposures over a substantial time period. Levels of hemoglobin adducts have been shown to be linearly related to dose for at least seven carcinogens of different types. Hemoglobin adduct levels have been shown to be related, within a factor of two, to DNA adduct levels in target tissues for three agents, ethylene oxide, trans-4-dimethylaminostilbene, and 2-acetylaminofluorene. Hemoglobin adducts therefore provide very useful complementary data to DNA adduct levels as measures of carcinogen exposure.
Certain attributes are indispensable for any methodology to be adequate in providing accurate, quantitative measurements of exposure to environmental carcinogens and at the same time fulfilling the objective of providing early indication of long-term cancer risk. Important among these attributes are the following: the analytical methods must be adequate to detect and quantify exposure to carcinogens/mutagens at ambient levels in the environment; they must be applicable to cells or body fluids that are readily accessible; measured values should be quantitatively related to exposure levels over a wide range; and they should integrate consequences of intermittent or continuous exposures to multiple agents. All of these attributes are applicable to accurate dosimetry of exposure alone. In order to be applicable also to the assessment of health risk, the methods should also be capable of detecting early biological effects predictive of long-term adverse health risks (i.e., cancer).
Current evidence indicates that available methodologies have the requisite sensitivity to detect and quantify levels of DNA and hemoglobin adducts of several classes of DNA-damaging agents in human tissues resulting from ambient levels of exposure. Specificity for the detection of compounds of known structure is a common feature of most of the methods, and some are suited to detect total DNA damage from multiple sources. Certain of the methods (e.g., immunoassays) are applicable to large numbers of samples, whereas others (e.g., postlabeling, thymine glycol analysis) are technically more complex and time-consuming. Validation will be required to avoid systematic errors in measurement when the methods are applied in large-scale epidemiologic studies. Methodologic attributes such as accuracy, reproducibility (intra-and interlaboratory), and applicability to stored samples will need to be determined by appropriately designed collaborative studies among laboratories. Additional factors such as variations of observed values due to age, sex, race, and other variables, as well as effects of possible interfering factors (e.g., diet, smoking, alcohol, etc.) will require definition through properly designed human studies of limited scope to facilitate interpretation of results of epidemiologic surveys.
Methods currently in use are applicable to detection of exposure: at present, none of them can be considered adequately validated to provide direct evidence of cancer risk. Strategies for the use of exposure information in the prospective assessment of genetic risk are important future challenges, and their development and validation will require a great deal of additional research.
